This study identified microRNAs (miRNAs) and mRNAs associated with Compound Longmaining (CLMN) treatment of acute myocardial infarction (AMI). Our results provide a theoretical framework to guide AMI treatment and improve myocardial injury.
Background
Coronary or ischemic heart disease is the result of coronary arterial atherosclerosis. The lesions caused by stenosis or obstruction can lead to ischemia, hypoxia, or necrosis. Acute myocardial infarction (AMI) is a more serious variant of coronary heart disease. AMI is a major cardiovascular disease that can seriously endanger human health worldwide. It has become one of the leading causes of death and disability in recent years [1] . It can induce myocardial cell remodeling, apoptosis, hypertrophy, fibrosis, and, ultimately, heart failure [2] .
The prescription of Compound Longmaining (CLMN) for the treatment of coronary heart diseases was established and validated in the clinic by Professor Gen-yu Tao (Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine). It consists of 4 traditional Chinese medicines (Puerariae lobatae radix, Dioscoreae nipponicae rhizoma, Chuanxiong rhizoma, and Propolis). Previous clinical studies have proved its efficacy for the treatment of AMI [3] . However, the specific mechanism of action of this formulation is still unclear. Therefore, it is important to explore the mechanism of action with respect to coronary heart disease.
Recently, many studies have been performed to understand AMI at the gene level. It is considered to be an extremely complex physiological and pathological process. The occurrence and development of AMI is a multilevel regulatory process happening at DNA, transcription, post-transcription, and protein expression levels. MicroRNAs (miRNAs) are endogenous regulatory RNA molecules that play an important role in the pathogenesis of AMI. They participate in a complex network of gene regulation through post-transcriptional negative regulation of the target RNA molecules and also in various pathophysiological processes with AMI and associated complications [4, 5] . This effect of miRNAs on mRNA is wellknown with respect to different physiological processes such as development, immunity, and neuronal activity [6] . Much evidence has also confirmed that small RNA-mediated RNA also regulates various diseases [7, 8] . Valuable information can be obtained regarding the mechanism of CLMN action on AMI by a detailed understanding of the expression profiles of the related mRNAs and miRNAs.
The present study used high-throughput sequencing techniques to assess expression profiles of miRNAs and mRNA in response to CLMN treatment of AMI. We assessed the correlation among differentially expressed microRNAs (DEMs) and genes (DEGs), and explored the regulatory role of mRNA and miRNAs to identify novel therapeutic targets.
Material and Methods
Animals A total of 18 male BALB/c mice, weighing 22-28 g, were purchased from the Animal Center of the Fourth Military Medical University (Shaanxi, China). The mice were allowed to acclimatize by keeping them under controlled humidity and temperature for 7 days. The protocol was approved by the Animal Ethics Committee of Shaanxi University of Chinese Medicine (Shaanxi, China).
Preparation of CLMN decoction
The CLMN decoction was prepared following a previously reported method [9] . Briefly, 48 g of each of the 4 traditional Chinese medicines were decocted in water (1: 14, w/v) twice, followed by condensation of the combined solution to 0.32 g/ml crude drug.
Model preparation and drug administration
All the animals were divided into 3 groups. The AMI model was established following a previously reported method [10, 11] . Briefly, the process included opening the pericardium and visualizing the left anterior descending coronary artery. A needle was inserted and the artery was ligated with 8/0 monofilament polypropylene suture 2 mm from the lower edge of the left atrial appendage, leading to permanent ischemia of the coronary artery below the ligation line. In the sham operation group, needles were inserted into the left anterior descending branch of the coronary artery after thoracotomy, but they were not ligated, and the other operation procedures were similar to those used in the AMI model group. The animals in both the sham and model groups were given normal saline. The CLMN group was given CLMN decoction (6.24 g/kg/day). Mice were observed for 3 weeks.
Sample collection
After 21 days of intragastric administration, mice were anesthetized and fresh heart specimens were collected. Each sample was divided into 2 parts for pathology and miRNA-seq, mRNA-seq analysis, and qPCR.
Histological analysis
The myocardial tissues were fixed in 10% neutral formaldehyde solution for 24 h, then they were embedded, sliced, and stained with hematoxylin-eosin (HE) and Masson Trichrome. All samples were examined using an optical microscope (Olympus Optical Co., Tokyo, Japan). Image Pro-Plus 6.0 (IPP 6.0) image processing software was used to calculate the percentage of MI area (Infarction area percentage=myocardial infarction area/left ventricular total area) in each group.
Small RNA sequencing
Total RNA was extracted from the myocardial tissues using Trizol (Invitrogen). The RNA molecules 18-30 nucleotides in size were enriched by polyacrylamide gel electrophoresis (PAGE). The 3'adapters were added and the 36-44 nucleotide long RNAs were enriched. The 5'adapters were also ligated to the RNAs. The reverse transcription products were separated by 3.5% agarose gel electrophoresis. We selected the 140-160 bp zone strip for cutting glue, and the gel recovery product is the final library. Illumina HiSeqTM 2500 was sequenced by Gene Denovo Biotechnology Co. (Guangzhou, China). DEMs was screened by P value (<0.05) and fold change (³1.5).
mRNA sequencing
RNA was extracted using Trizol (Invitrogen). Magnetic beads with Oligo (dT) were used to enrich the mRNA and to add fragmentation buffer to the obtained mRNA to make the fragment become a short fragment, and then the first strand of cDNA was synthesized by six-base random primer (random hexamers) using the mRNA as the template. The second strand of cDNA was synthesized by adding buffer, dNTPs, RNase H, and DNA polymerase I. The second strand of cDNA was purified by QiaQuick PCR kit and eluted with EB buffer. The end was repaired, base A was added, a sequencing junction was added, and then the target fragment was recovered by agarose gel electrophoresis. PCR amplification was carried out to complete the preparation of the whole library. The constructed library was sequenced with Illumina HiSeqTM 2500. DESeq software was used to identify DEGs in pair-wise comparisons with fold change (FC) ³1.5 and false discovery rate (FDR) £0.25 [12, 13] .
Quantitative real-time PCR validation
To validate the expression profiles of the 6 miRNAs and 9 mRNAs obtained by miRNA-Seq and mRNA-Seq, qRT-PCR was performed using U6 and b-actin as references. The results were calculated using the comparative Ct (2 -DD Ct) method [14] . The qPCR reaction procedure is shown in Table 1 . The qPCR primer sequences are shown in Supplementary Tables 1 and 2.
Prediction of miRNA-targeted genes and construction of miRNA-mRNA network
The DEMs were used to identify potential target genes by searching the RNAhybrid (v2.1.2) +svm light (v6.01), Miranda (v3.3a), and TargetScan (Version: 7.0) software. The data providing details about the intersection of DEMs target genes and DEGs were obtained. Cytoscape 3.6.1 software was used for network construction of miRNA-mRNA interaction.
GO Analysis and KEGG Pathway Analysis
The DEGs were input into Blast2GO (https://www.blast2go. com/) and Blastall (http://www.kegg.jp/) software for Gene Ontology (GO) analysis and Kyoto Encyclopedias of Genes and Genomes (KEGG) pathway enrichment analysis, respectively.
Statistical analysis
All results are expressed as mean±standard deviation. One-way ANOVA was used to compare the results of multiple groups. All statistical analysis was carried out by SPSS 19.0 software. P value less than 0.05 indicates that there was a statistically significant difference.
Results

Effect of CLMN on pathological changes
Masson trichrome staining results ( Figure 1B, 1D) shown that the myocardial cells in S group were neatly arranged and clearly structured, with no proliferation of fibroblasts. The M group revealed an obvious myocardial interstitial collagen deposition along with severe myocardial fibrosis. As compared to the M group, significant reduction in the proliferation of cardiac fibroblasts and in myocardial interstitial fibrosis was observed in the T group. The HE staining suggests ( Figure 1A, 1C ) that the myocardial cells in the S group had clear cross-striation, uniform staining, and orderly arrangement. However, the myocardial tissue in the M group was seriously damaged, had uneven staining, blurred cross-striation, disordered arrangement, a large amount of cellular infiltration, and flaky necrosis, and the cell nuclei were smaller. Overall, the inflammatory symptoms were found to be largely alleviated in the T group. According to Figure 1E , the area of MI significantly decreased after the treatment of CLMN.
Identification of DEGs and DEMs
As shown in Figure 2B of reads in each sample was also calculated (Supplementary Table 4 ).
Validation of the sequencing data by quantitative RT-PCR
Quantitative RT-PCR (QRT-PCR) was used to verify the accuracy of transcriptome sequencing results. A total of 9 DEGs and 6 DEMs were selected based upon RNA-Seq and miRNA-seq data. These included CNN1, LTBP2, ACE, SMOC1, SOST, FSTL1, LOX, MMP-3, SCD4, mir-22-y, mir-495-y, mir-133-x, mir-144-y, mir-136-y, and mir-3966-x. Findings of QRT-PCR were corroborated by RNA-seq and miRNA-seq results (Figure 4 ).
GO analysis and KEGG pathway enrichment analysis were performed for DEGs
In order to elucidate the correlation between the DEGs and effects of the CLMN treatment on AMI, GO and signal pathway analysis were performed. Findings of the GO analysis showed that 61 down-regulated genes have different biological functions involved in regulation, single-organism process, cellular process, binding, and catalytic activity ( Figure 5 , Supplementary  Table 5 ). KEGG signaling pathway analysis demonstrated that 76 DEGs were distributed in the 42 pathways, including Arachidonic acid metabolism, protein digestion and absorption, focal adhesion, ECM-receptor interaction, PI3K/Akt-, PPAR-, and TNF-signaling pathway (Figure 6 , Supplementary Table 6 ). Table 7 ).
Target prediction and construction of a regulatory and interaction network
We screened 76 DEGs by RNA-seq. Numerous studies have confirmed that miRNAs can regulate the degradation of RNA or inhibit its translation. Therefore, the expression level of miRNAs should be contrary to that of their target genes. Using this regulation mechanism, we intersected the transcriptome differential gene pool and the target gene pool of the difference obtained by the sequencing of miRNAs and found the overlapping genes of the 2 pools. Then, we determined the downregulated differential target genes according to the up-regulation of miRNAs and up-regulated differential target genes by down-regulation of miRNAs. Relevance analysis showed that 9 of the 22 miRNAs were associated with differentially targeted genes, of which 8 were up-regulated (mir-3966-x, mir-4510-x, novel-m0002-5p, mir-144-y, mir-378d, mir-136-y, mir-22-y, and mir-133-x), and 1 was down-regulated (mir-495-y). However, because of the one-to-many, many-to-one relationship between miRNAs and RNA targeting regulation, single miRNAs can target multiple genes, and multiple miRNAs can target one gene. Therefore, not every gene targeted by up-regulated miRNAs is under-expressed, and every gene targeted by down-regulated miRNAs is over-expressed. Ultimately, we found 18 downregulated genes (CST6, BACE2, WSCD2, FSTL1, P4HA3, CDH22, LTBP2, GM14296, DBN1, SOST, SRPX2, COL8A2, SMOC1, LOX, CNN1, COL4A3, ADAMTS8, and GDF6), and 2 up-regulated genes (SCD4 and PAX9). We then constructed a miRNA-gene interaction network based on the correlation between DEMs and DEGs expression ( Figure 7 ).
Discussion
AMI is a serious and life-threatening cardiovascular disease that is associated with high morbidity, disability, and mortality. AMI is considered not only a common clinical emergency but also a public health problem that can endanger human health [15] and it is imperative to find an effective treatment for AMI. Previous studies have found that CLMN has protective effects on acute myocardial ischemia-hypoxia injury. In rats, it has been shown to resist thrombosis, improve microcirculation, and has protective effects on AMI [16] . In this study, we first used sequencing technology to screen DEMs and DEGs involved in the treatment of AMI. Finally, the differentiated miRNAs-mRNA regulatory network was constructed. Our findings have great relevance in deciphering the molecular mechanism associated with CLMN treatment of AMI. A total of 76 DEGs were obtained in this study. GO functional analysis of DEGs suggests these were mainly involved in biological regulation, single-organism process, cellular process, binding, catalytic activity, and extracellular region. The KEGG analysis revealed that the most significant enrichment pathways related to AMI were focal adhesion [17] , PI3K-Akt signaling pathway [18] , PPAR signaling pathway [19] , ECM-receptor interaction [20] , Arachidonic acid metabolism [21] , and TNF signaling pathway [22] . Overall, this analysis suggests that the treatment of AMI by CLMN may operate through a variety of cellular responses and multiple pathways.
The development of AMI is a complicated process that may be regulated by multiple genes. In recent years, research interest in miRNAs has grown. In this study, 22 DEMs were selected, among which some miRNAs have been reported to play a role in AMI. Studies have demonstrated that mir-22 can prevent myocardial oxidative stress and can regulate cardiac apoptosis, hypertrophy, fibrosis, and regeneration [23] [24] [25] [26] . mir-378 can inhibit the MAPK signal transduction pathway and control myocardial hypertrophy by acting on MAPK1, insulin-like growth factor-1 receptor, growth factor receptor-binding protein-2, and Ras kinase inhibitor-1 [27] . mir-133 inhibits myocardial fibrosis by reducing the connective tissue growth factor gene and fibrin synthesis [28] . mir-144 analogues transfected into rat H9C2 cardiomyocytes can reduce cell proliferation and increase apoptotic rate by enhancing Caspase-3 activity [29] , suggesting its potential utility as a gene promoting cardiomyocyte apoptosis. Studies have reported that mir-378 can inhibit the expression of caspase-3, which can reduce cardiomyocyte ischemic injury, suggesting its utility as a potential therapy target [30] .
Regulation of the miRNAs target genes is very important. miRNAs degrade target genes at the post-transcriptional level and inhibit their expression [31] . According to the results of combined analysis of mRNAs and miRNAs, a single miRNAs can regulate multiple target genes, such as mir-3966-x, mir-4510-x, novel-m0002-5p, mir-144-y, and mir-22-y. Bioinformatics analysis showed that a total of 9 miRNAs participated in the construction of the miRNAs-mRNAs regulatory network. These 9 miRNAs had 20 target genes, including FSTL1, LOX, CNN1, ADAMTS8, LTBP2, and other genes closely related to AMI. Studies have shown that myocardial ischemia and hypoxia can induce the expression of FSTL1 and promote compensatory vascular remodeling [32] . Li et al. [33] found that myocardial ischemia/reperfusion injury can increase expression of LOX-1 in the myocardium. The application of an antibody antagonizing LOX-1 function can significantly reduce myocardial injury and infarction size. Wagsater et al. demonstrated enhanced ADAMTS8 expression in carotid atherosclerotic and unstable coronary plaques [34] , and Gabrielsen et al. [35] found significantly higher LTBP2 levels in patients with heart failure.
Conclusions
In this study, we established the expression profiles of DEMs and DEGs in cardiac tissues. A single miRNA can regulate multiple RNAs and a single RNA can be regulated by multiple miRNAs. They interact to form a complex regulatory network and play a role in the development of AMI. The findings of our study provided a basis for the pathogenesis, clinical treatment, and prognosis of CLMN in the treatment of AMI.
Our results also provide a theoretical basis for screening the CLMN targets with respect to AMI and provide a platform for the screening of markers. 
